Corporate news announcement processed and transmitted by Hugin AS.
The issuer is solely responsible for the content of this
announcement.
----------------------------------------------------------------------
--------------
aap Implantate AG, a medical technology company listed on the
Frankfurt Stock Exchange in the Prime Standard segment, achieved in
the fourth quarter of the financial year 2008 - according to
preliminary figures - quarterly sales of EUR 7.1 million (- 24% to
fourth quarter 2007). In contrast to the fourth quarter 2008, the
fourth quarter 2007 was influenced by more orders from global
partners. Total sales of the financial year 2008 went up to EUR 31.2
million, a year-to-year increase of 11%.
In 2008, the group companies active in the field of medical
biomaterials ("aap bio implants group"), achieved sales of EUR 19.4
million (previous year: EUR 18.8 million, + 3%). This development is
based on the considerably cautious customers' order behavior
(reduction of inventories) as well as delays in planned approvals of
new products.
The Berlin based trauma & orthopaedics division of the company
reached for the full financial year 2008 a strong organic sales
increase of 28% to EUR 11.8 million (previous year: EUR 9.2 million).
+-------------------------------------------------------------------+
| In EUR million | 2008 | 2007 | Changes |
|--------------------------------+----------+----------+------------|
| Fourth quarter sales | 7.1 | 9.4 | - 24% |
|--------------------------------+----------+----------+------------|
| Financial year sales | 31.2 | 28.0 | + 11% |
|--------------------------------+----------+----------+------------|
| * thereof trauma & | 11.8 | 9.2* | + 28% |
| orthopaedics | | | |
|--------------------------------+----------+----------+------------|
| * thereof aap bio | 19.4 | 18.8* | + 3% |
| implants group | | | |
|-------------------------------------------------------------------|
| * Variational presentation to the segment report as of 31st of |
| December 2007 results in the modified presentation of the |
| distribution of a product. |
+-------------------------------------------------------------------+
The publication of the full annual financial statements 2008 is
planned for April 17, 2009.
___________
aap is a medical technology company that develops, manufactures and
markets biomaterials and implants for trauma and orthopaedics. Its
product portfolio includes bone cements, bone graft substitutes,
antibiotical carriers, implants for fracture healing and joint
replacement. In addition to its Berlin headquarters the company has
locations in Dieburg and Obernburg near Frankfurt am Main, Dusseldorf
as well as at Nijmegen in the Netherlands. aap Implantate AG has been
listed in the Prime Standard segment at the Frankfurt stock exchange
since May 16, 2003.
Please address any queries to:
aap Implantate AG, Nanette Hüdepohl, Investor & Public Relations,
Lorenzweg 5, 12099 Berlin, Germany
Tel.: +49 30 7501 9133; fax: +49 30 7501 9290; n.huedepohl@aap.de
--- End of Message ---
aap Implantate AG
Lorenzweg 5 Berlin Germany
WKN: 506660; ISIN:
DE0005066609; Index: CDAX, Prime All Share, TECH All Share;
Listed: Geregelter Markt in Frankfurter Wertpapierbörse, Prime
Standard in Frankfurter Wertpapierbörse,
Freiverkehr in Börse Berlin, Freiverkehr in Börse Düsseldorf,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg, Freiverkehr
in Niedersächsische Börse zu Hannover,
Freiverkehr in Bayerische Börse München, Freiverkehr in Börse
Stuttgart;
Copyright © Hugin AS 2009. All rights reserved.